MindMaze Therapeutics is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. Headquartered in Geneva, it was formed in 2025 through a combination between NeuroX Group SA (NeuroX), the successor of MindMaze, and Relief Therapeutics. In 2025, NeuroX acquired strategic assets of MindMaze Group SA and MindMaze SA (MindMaze), including intellectual property and the MindMaze® brand.
The fully-integrated group is dedicated to advancing precision medicine across neurology and rare diseases, with the MindMaze neurotherapeutics platform at the heart of its innovation and growth strategy.
MindMaze has developed evidence-based, next-generation neurotherapeutics that provide disease-modifying motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. Typical indications include stroke, Parkinson’s disease, and at-risk aging.
These neurotherapeutics are delivered through proprietary software and hardware, underpinned by an advanced brain technology platform that integrates wearables and sensors, and provides digital assessments as well as telehealth services.
The unique suite of MindMaze solutions is delivered globally across the continuum-of-care, both in-clinic and in patients’ homes, to successfully address some of neurology’s biggest challenges. MindMaze has already partnered with leading pharmaceutical companies to use its proprietary technology across multiple clinical trials.
MindMaze has raised and invested more than USD 350 million during the last decade to secure robust clinical evidence, demonstrate significant medico-economic outcomes, and market its disease-modifying neurotherapeutics platform.
In the United States of America, MindMaze has received a unique reimbursement code (CAT-3) to support the delivery of its home-based neurotherapeutic training.
The company’s R&D pipeline focuses on adjacent neurological diseases, such as spinal cord injury, multiple sclerosis, traumatic brain injury, and Alzheimer’s disease/dementia.
Moved by the mission to accelerate the brain’s ability to recover, learn and adapt, the MindMaze platform innovates by combining software-delivered behavioral treatments, drugs, devices, data, and AI to establish a new paradigm of precision medicine in neurology and neural repair.
Augmenting its position as a global leader in neuroscience, MindMaze leverages Relief Therapeutics’ proven expertise in drug repurposing and advanced delivery systems to address critical unmet needs in rare dermatological, metabolic, and respiratory disorders.
This innovative, dual-engine model, which unites MindMaze’s brain repair paradigm with targeted rare disease therapeutics, enables transformative patient outcomes through strategic collaborations, ongoing clinical development, and global commercialisation via licensing and distribution agreements.
Listed on the SIX Swiss Exchange under the ticker MMTX, MindMaze is committed to accelerating human recovery and enhancing quality of life for patients with neurological and rare conditions across the world.
In less than ten years, we have transformed care for debilitating neurological diseases. Our plans for the next ten years are just as ambitious.